GlaxoSmithKline plc (LON:GSK) has been given a GBX 1,890 ($23.79) target price by investment analysts at Berenberg Bank in a report released on Monday. The firm currently has a “neutral” rating on the stock. Berenberg Bank’s price target suggests a potential upside of 20.73% from the stock’s current price.

A number of other equities research analysts also recently commented on the company. HSBC Holdings plc reaffirmed a “buy” rating and issued a GBX 1,970 ($24.80) price objective on shares of GlaxoSmithKline plc in a research report on Wednesday, March 15th. Kepler Capital Markets set a GBX 1,500 ($18.88) price objective on GlaxoSmithKline plc and gave the company a “sell” rating in a research report on Thursday, March 9th. Jefferies Group LLC lifted their price objective on GlaxoSmithKline plc from GBX 1,800 ($22.66) to GBX 1,900 ($23.91) and gave the company a “buy” rating in a research report on Thursday, March 9th. Liberum Capital reaffirmed a “buy” rating and issued a GBX 1,900 ($23.91) price objective on shares of GlaxoSmithKline plc in a research report on Thursday, March 9th. Finally, Barclays PLC initiated coverage on GlaxoSmithKline plc in a research report on Wednesday, March 8th. They issued an “equal weight” rating and a GBX 1,550 ($19.51) price objective for the company. Three investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of GBX 1,739.27 ($21.89).

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

GlaxoSmithKline plc (LON:GSK) opened at 1565.50 on Monday. GlaxoSmithKline plc has a 1-year low of GBX 1,363.00 and a 1-year high of GBX 1,745.56. The company’s market capitalization is GBX 76.20 billion. The firm has a 50-day moving average price of GBX 1,657.88 and a 200 day moving average price of GBX 1,595.46.

The firm also recently disclosed a dividend, which was paid on Thursday, April 13th. Stockholders of record on Thursday, February 23rd were given a dividend of GBX 23 ($0.29) per share. The ex-dividend date of this dividend was Thursday, February 23rd. This is an increase from GlaxoSmithKline plc’s previous dividend of $19.00. This represents a dividend yield of 1.47%.

COPYRIGHT VIOLATION WARNING: This story was reported by Marea Informative and is the property of of Marea Informative. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at http://www.mareainformativa.com/berenberg-bank-reitera-gbx-1890-precio-objetivo-para-plc-de-glaxosmithkline-gsk/108884/.

In other news, insider Dominic Redfern bought 230 shares of the business’s stock in a transaction on Thursday, April 13th. The stock was purchased at an average cost of GBX 1,639 ($20.63) per share, for a total transaction of £3,769.70 ($4,744.75). Also, insider Victoria Whyte sold 4,820 shares of the company’s stock in a transaction that occurred on Thursday, February 9th. The stock was sold at an average price of GBX 1,576 ($19.84), for a total value of £75,963.20 ($95,611.33). Over the last quarter, insiders have bought 718 shares of company stock valued at $1,173,224 and have sold 52,038 shares valued at $84,442,106.

About GlaxoSmithKline plc

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Receive News & Stock Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related stocks with our FREE daily email newsletter.